Axoltis says its Phase 2 study for an experimental ALS drug failed
The French biotech Axoltis Pharma reported a Phase 2 failure in ALS on Tuesday morning, but suggested it found a small signal to move the drug forward amid a noisy dataset. Researchers were testing whether ...
Vera Therapeutics announced on Tuesday that their recently approved drug Trutakna demonstrated strong results in a Phase 3 clinical trial for patients with IgA nephropathy, a chronic autoimmune kidney disease. The two-year study showed that Trutakna stabilized kidney function and reduced the risk of kidney-related death and other complications.
Following the FDA's accelerated approval in July for treating IgAN, which leads to progressive kidney function loss and potentially organ failure requiring dialysis, Vera plans to seek full approval of the drug during the fourth quarter.
Brief written by urgent.news from STAT News's own syndicated text. Machine-written — may contain errors; check the original before relying on it.
This story
This is one outlet's version. Read the fullest account.
